Drug Trial Radar · NCT05555589
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Apr 11, 2023
Primary completion
Jul 28, 2026
Study completion Jul 28, 2026
Sponsor
- Lead sponsor
- ReGenTree, LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Conditions
- Neurotrophic Keratopathy
Interventions
RGN-259Drug
A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into study eye(s), five times per day for 28 days
PlaceboDrug
It is composed of the same excipients as RGN-259 but does not contain Tβ4. Direct instillation into study eye(s), five times per day for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects achieving complete healing of PED at Day 29Time frame: Day 29
Locations
50 sites in 4 countries. Site status is shown where the registry gives one.
Parker Cornea
Vestavia Hills, Alabama
Harvard Eye Associates
Laguna Hills, California
Loma Linda University Eye Institute
Loma Linda, California
Nvision Clinical Research, LLC
Los Angeles, California
Retina Consultants of Southern Colorado
Colorado Springs, Colorado
Advance Vision Research Institute
Longmont, Colorado
Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons
Danbury, Connecticut
Nature Coast Clinical Research
Crystal River, Florida
University of Miami - Bascom Palmer Eye Institute, Miami
Miami, Florida
University of South Florida, Ophthalmolgoy
Tampa, Florida
Thomas Eye Group, P.C.
Sandy Springs, Georgia
Northwestern
Chicago, Illinois
Midwest Cornea Associates, LLC.
Carmel, Indiana
Huffman & Huffman, PSC
Lexington, Kentucky
The Johns Hopkins Wilmer Eye Institute
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Midwest Vision Research Foundation
Chesterfield, Missouri
Washington University Eye Center
St Louis, Missouri
Atlantic Eye
Eatontown, New Jersey
Metropolitan Eye Research and Surgery Institute
Palisades Park, New Jersey
Montefiore Medical Center
The Bronx, New York
Duke Eye Center
Durham, North Carolina
Oculus Research
Raleigh, North Carolina
CORE, Inc. / Vita Eye Clinic
Shelby, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Cleveland Clinic, Cole Eye Institute
Cleveland, Ohio
Pacific ClearVision Institute
Eugene, Oregon
Cataract & Laser Institute of Southern Oregon
Medford, Oregon
OHSU Casey Eye Institute
Portland, Oregon
Scheie Eye Institute, University of Pennsylvania
Philadelphia, Pennsylvania
UPMC Eye Center
Pittsburgh, Pennsylvania
Black Hills Regional Eye Institute
Rapid City, South Dakota
Vanderbilt Eye Institute
Nashville, Tennessee
Cornea Associates of Texas
Dallas, Texas
Houston Eye Associates
Houston, Texas
CliniVerse Research
Mission, Texas
Stuart Terry Eye Associates
San Antonio, Texas
MCOA Eye Care
San Antonio, Texas
Berkeley Eye Center
Sugar Land, Texas
Virginia Eye Consultants
Norfolk, Virginia
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.